Aeolian Therapeutics, Inc.

LINCOLN, Neb.--( BUSINESS WIRE )--Aeolian Biotech Corp. today announced that Tyler Martin, M.D., Chief Executive Officer of Aeolian, will present a Company overview at the BIO CEO & Investor Conference on Monday, February 6, 2023 at 10:15 am ET. The conference is being held at the New York Marriott Marquis in New York City, February 6-7, 2023. Investors interested in arranging a meeting with company management can do so as registered conference participants through the BIO CEO & Investor Conference website at https://www.bio.org/events/bio-ceo-investor-conference/sessions or by emailing Ian Frost at Ian.Frost@Westwicke.com . Aeolian’s presentation may be accessed from the Company's website at www.aeolianbiotech.com . About Aeolian Biotech Corp. Aeolian is committed to the development of an improved pneumococcal conjugate vaccine to address the threat of circulating and emerging pneumococcal serotypes.

LINCOLN, Neb.--(BUSINESS WIRE)-- Aeolian Biotech Corp. today announced that Tyler Martin, M.D., Chief Executive Officer of Aeolian, will present a Company overview at the BIO CEO & Investor Conference on Monday, February 6, 2023 at 10:15 am ET. The conference is being held at the New York Marriott Marquis in New York City, February 6-7, 2023. Investors interested in arranging a meeting with company management can do so as registered conference participants through the BIO CEO & Investor Conference website at or by emailing Ian Frost at Ian.Frost@Westwicke.com. Aeolian’s presentation may be accessed from the Company's website at . About Aeolian Biotech Corp. Aeolian is committed to the development of an improved pneumococcal conjugate vaccine to address the threat of circulating and emerging pneumococcal serotypes.